REV-ERB raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-26. Anything still debated is marked as such rather than presented as settled.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
=== Low-profile chains === Low-profile chains are chains with low teeth and safety elements between teeth. These chains are used on consumer and small professional saws for non-experienced operators. These chains are more insensitive against dirt, but require more frequent sharpening.
oryzae with altered properties were generated by irradiation or by the CRISPR/CAS method. Similarly, mutants of A. sojae with altered properties were generated by a variant of the CRISPR/Cas method or chemical mutagenesis.
In eukaryotes, NADH is the most important electron donor. The associated electron transport chain is NADH → Complex I → Q → Complex III → cytochrome c → Complex IV → O2 where Complexes I, III and IV are proton pumps, while Q and cytochrome c are mobile electron carriers. The electron acceptor for this process is molecular oxygen. In prokaryotes (bacteria and archaea) the situation is more complicated, because there are several different electron donors and several different electron acceptors. The generalized electron transport chain in bacteria is:
=== Anna Gearing === Anna Gearing (Elena Saurel) is the head of FutureDawn Partners, a socially conscious investment fund. Despite her ethical business philosophy, Anna is shown to have expensive personal tastes, and micromanages employees at her fund. She has two daughters, with her longtime portfolio manager Petra Koenig as their godmother. Anna first appears as a client of Pierpoint, with Yasmin Kara-Hanani hedging her FX exposure. Harper meets Anna at a Pierpoint-organized duck shoot in Wales tied to healthcare startup Rican, where Anna bluntly assesses Rican as fundamentally underperforming and incapable of delivering on its social mission. Harper uses this insight to convince Jesse Bloom to buy out Anna’s stake—after already selling him $3.3 billion in shares—securing his controlling interest and long-term profit. After Harper is fired from Pierpoint, she joins FutureDawn as Anna’s executive assistant, but quickly aligns herself with Petra, who grows disillusioned with Anna’s leadership. Tensions peak when Harper helps Petra hedge Lumi IPO exposure by buying credit default swaps on fossil-fuel assets, directly contradicting FutureDawn’s ethical stance. Harper and Petra ultimately break away to form their own hedge fund, publicly announcing the move at a Swiss climate conference attended by Anna.
On 21 March 2020, Bukele imposed a 30-day nationwide lockdown in an effort to combat the pandemic. During the lockdown, 4,236 people were arrested by the National Civil Police for violating the lockdown order; 70 were arrested before the lockdown order became public. The arrestees were quarantined in a "containment center". Human rights organizations such as Human Rights Watch criticized the arrests, citing instances of arbitrary arrests and abuse by police. Amid April 2020 lockdowns in the country's prisons and published images of prisoners lined up in cramped positions, Human Rights Watch called the prisons' living conditions "inhumane" (particularly in light of the pandemic). On 27 May 2020, the United States donated 250 ventilators to El Salvador. During a press conference where Bukele received the ventilators, he said that he took hydroxychloroquine as prophylaxis and added that "most of the world's leaders use [hydroxychloroquine] as a prophylaxis". Bukele inaugurated the Hospital El Salvador, the largest hospital in Latin America used exclusively for treating cases of COVID-19 at the site of the former International Center for Fairs and Conventions, on 22 June 2020. The hospital had a capacity of 400 beds, 105 intensive-care units, and 295 intermediate-care units staffed by 240 doctors. In August 2020, the hospital's capacity was increased by 575 beds. It began treating conditions other than COVID-19 by June 2022.
Sources: en.wikipedia.org
=== Walter Bennett === Dr. Walter Bennett (voiced by Harry S. Robins) is a Black Mesa scientist. He is seen in Half-Life: Blue Shift. In Blue Shift, Dr. Bennett is seen fixing a battery in Dr. Rosenberg's office, along with Dr. Simmons. The three scientists soon get it fixed with the help of Barney Calhoun, and they start their teleportation out of Black Mesa. The four successfully make it out of the facility, making Dr. Bennett one of the few known survivors of the incident. They open the gates and start their journey to the outside world with an SUV. Dr. Bennett is briefly mentioned in Half-Life: Opposing Force. As Adrian Shephard traverses within Sector E of Black Mesa, he enters a testing laboratory where Xen specimens were being experimented on prior to the Resonance Cascade. He opens up a transmission intended for Dr. Bennett, revealing a hologram of a scientist talking about the results of an experiment conducted on a Barnacle, which was one of the Xen creatures being examined. Following the transmission, Shephard takes a nearby Barnacle specimen that was intended for Dr. Bennett to experiment on before the Resonance Cascade. Dr. Bennett's final fate is unknown.
=== Body odor and acne === Rising levels of androgens can change the fatty acid composition of perspiration, resulting in a more "adult" body odor. This often precedes thelarche and pubarche by one or more years. Another androgen effect is increased secretion of oil (sebum) from the skin. This change increases the susceptibility to acne, a skin condition that is characteristic of puberty. Acne varies greatly in its severity.
the Standing Committee on Finance; the Election Committee; and the Committee of Privileges. The first session passed the Kuala Lumpur City Bill, the Transfer of Power Bill, and the Loan and Debt Bill.
In addition to being multi-varied and extraordinarily intense, these new dyes were notoriously unstable, rapidly fading and turning when exposed to sunlight, washing, and other chemical or physical agents. This led to new systems of categorization and study of colorants, which in turn lead to the synthesis of more color-fast modern colorants. Synthetic colors found themselves in not only dyes and paints but also inks and foodstuffs, permeating consumer culture.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.